Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

121. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis. (PubMed)

Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis. Cardiac shock is the leading cause of death in patients with acute myocardial infarction. The objective of this systematic review and meta-analysis was to evaluate whether levosimendan, compared to any type of control, is associated with improved clinical outcomes in patients with cardiogenic shock complicating myocardial infarction.The PubMed, EMBASE, Cochrane Central Register, and China (...) National Knowledge Information databases were searched for pertinent studies published up until 1 May 2016. Randomized and non-randomized clinical trials comparing levosimendan to standard therapy or placebo, in adult patients with cardiogenic shock complicating myocardial infarction, and reporting at least one outcome of interest were included. The primary outcome was mortality, whereas secondary outcomes were length of ICU stay, SOFA score, cardiac index (CI), cardiac power index (CPI), ejection

2017 Medicina intensiva

122. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. (PubMed)

Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. Objective To evaluate how selection of patients for high sensitivity cardiac troponin testing affects the diagnosis of myocardial infarction across different healthcare settings.Design Prospective study of three independent consecutive patient populations presenting to emergency departments.Setting Secondary and tertiary care hospitals in the United Kingdom (...) and United States.Participants High sensitivity cardiac troponin I concentrations were measured in 8500 consecutive patients presenting to emergency departments: unselected patients in the UK (n=1054) and two selected populations of patients in whom troponin testing was requested by the attending clinician in the UK (n=5815) and the US (n=1631). The final diagnosis of type 1 or type 2 myocardial infarction or myocardial injury was independently adjudicated.Main outcome measures Positive predictive value

Full Text available with Trip Pro

2017 BMJ

123. Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction

Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly after acute myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to cTn in the early diagnosis of AMI.Unselected patients (N=1954) presenting to the emergency department with symptoms

Full Text available with Trip Pro

2017 EvidenceUpdates

124. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. (PubMed)

PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.In this multicenter trial, we randomly (...) assigned 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. The primary end point was a composite of death or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Safety end points included bleeding and stroke.At 30 days, the composite

Full Text available with Trip Pro

2017 NEJM

125. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial (PubMed)

Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial Dual anti-platelet therapy represents standard care for treating patients with ST-segment elevation myocardial infarction (STEMI). Ticagrelor is a direct-acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation.To evaluate whether chewing a loading dose (LD) of ticagrelor, 180 mg, vs traditional oral

Full Text available with Trip Pro

2017 JAMA cardiology

126. Stem cell transplantation dose in patients with acute myocardial infarction: A meta-analysis. (PubMed)

Stem cell transplantation dose in patients with acute myocardial infarction: A meta-analysis. To evaluate whether stem cell transplantation improves global left ventricular ejection fraction (LVEF) in patients with acute myocardial infarction (AMI), and to determine the appropriate stem cell therapy dose as well as the effective period after stem cell transplantation for therapy.A systematic literature search included Pubmed, MEDLINE, China National Knowledge Infrastructure (CNKI), Chinese

Full Text available with Trip Pro

2017 Chronic diseases and translational medicine

127. Myocardial infarction in intensive care units: A systematic review of diagnosis and treatment. (PubMed)

Myocardial infarction in intensive care units: A systematic review of diagnosis and treatment. Patients in the intensive care unit are vulnerable to myocardial injury from a variety of causes, both ischaemic and non-ischaemic. It is challenging for ICU clinicians to apply the conventional guidance concerning diagnosis and treatment. We conducted this review to examine the evidence concerning diagnosis and treatment of myocardial infarction in the ICU.A systematic review was performed (...) to treatment was limited. A potential strategy to diagnose myocardial infarctions in the ICU is proposed.

Full Text available with Trip Pro

2017 Journal of the Intensive Care Society

128. Comparison of Outcomes of ST-Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention During Off-Hours Versus On-Hours

Comparison of Outcomes of ST-Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention During Off-Hours Versus On-Hours Previous studies have reported worse outcomes and longer door-to-balloon times (DBTs) in patients presenting with ST-elevation myocardial infarction (STEMI) after normal working hours, during weekends, and on holidays (off-hours) compared with normal business hours (on-hours). Recent studies, however, have reported similar outcomes regardless (...) , recurrent myocardial infarction (MI), and major adverse cardiovascular events (MACEs). A total of 86,776 patients (62 years and 74.5% male) were identified from 39 studies. There was no significant difference between both groups with regard to mean DBT (odds ratio [OR] 0.74, 95% confidence interval [CI] -2.73 to 4.22, p = 0.67) or median DBT (p = 0.19). There was no significant difference between the 2 groups for short-term end points including mortality (OR 1.11, 95% CI 0.99 to 1.25, p = 0.08), MI

2017 EvidenceUpdates

129. Supplemental Oxygen in Acute Myocardial Infarction

Supplemental Oxygen in Acute Myocardial Infarction Emergency Medicine > Journal Club > Archive > September 2017 Toggle navigation September 2017 Supplemental Oxygen in Acute MI Vignette You're working a shift in TCC one morning when EMS brings in a patient are with chest pain and a "possible" STEMI. They wheel the patient in transfer him to the stretcher, at which time you notice that the patient is not on oxygen. Remembering from medical school that everyone gets ABCs, IV, O2, and monitor (...) if there has been any new evidence since this journal club, you perform your own search of the literature... PICO Question Population : Prehospital or emergency department patients with acute myocardial infarction "normal" oxygen saturation. Intervention : Supplemental oxygen administration. Comparison : Room air Outcome : Mortality, length of stay, functional status, presence of clinically significant cardiac dysfunction. Search Strategy After choosing one obscure article from the 2012 journal club

2017 Washington University Emergency Medicine Journal Club

130. Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. (PubMed)

Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling. Publicly reported hospital risk-standardized mortality rates (RSMRs) for acute myocardial infarction (AMI) are calculated for Medicare beneficiaries. Outcomes for older patients with AMI may not reflect general outcomes.To examine the relationship between hospital 30-day RSMRs for older patients (aged ≥65 years) and those for younger patients (aged 18 to 64 years) and all patients (aged

2017 Annals of Internal Medicine

131. Migraines and Myocardial Infarction in Women

Migraines and Myocardial Infarction in Women "Migraines and Myocardial Infarction in Women" by Haley Moak < > > > > > Title Author Date of Graduation Summer 8-12-2017 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Heart disease is the number 1 cause of death for U.S. women, myocardial infarction (MI) included. It has been established that ischemic stroke has a positive correlation with those who experience migraines (...) , but there were no definitive studies saying that migraines cause all other cardiovascular related diseases, even though there is a common consensus that migraines are a vascular phenomenon. This systematic review focuses on the correlation between migraines and myocardial infarction particularly in women. Methods: An exhaustive search of available medical literature was conducted using MEDLINE-Ovid, Web of Science, and CINAHL databases. The following terms were searched as keywords: migraine, myocardial

2017 Pacific University EBM Capstone Project

132. Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation

Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation 07 January 2018 Article Contents Article Navigation 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Borja Ibanez (Chairperson) (Spain) * Corresponding authors

Full Text available with Trip Pro

2017 European Society of Cardiology

133. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute

Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute Timely primary percutaneous coronary intervention (PPCI) cannot be offered to all patients with ST-segment-elevation myocardial infarction (STEMI). Pharmaco-invasive (PhI) strategy has been proposed as a valuable alternative for eligible (...) patients with STEMI. We conducted a randomized study to compare the efficacy and safety of a PhI strategy with half-dose fibrinolytic regimen versus PPCI in patients with STEMI.The EARLY-MYO trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction) was an investigator-initiated, prospective, multicenter, randomized, noninferiority trial comparing a PhI strategy with half-dose alteplase versus PPCI in patients with STEMI 18

Full Text available with Trip Pro

2017 EvidenceUpdates

134. Sex differences in survival after myocardial infarction in Sweden, 1987-2010

Sex differences in survival after myocardial infarction in Sweden, 1987-2010 In this nationwide study, we investigated age-specific and sex-specific trends in sex differences in survival after acute myocardial infarction (AMI), including deaths from coronary heart disease (CHD) that occurred outside hospital.Observational study in Sweden of 28-day and 1-year mortality among 658 110 persons (35.7% women) aged 35-84 years with a first-time CHD event 1987-2010 with data retrieved from the national

Full Text available with Trip Pro

2017 EvidenceUpdates

135. Oxygen Therapy in Suspected Acute Myocardial Infarction. (PubMed)

Oxygen Therapy in Suspected Acute Myocardial Infarction. The clinical effect of routine oxygen therapy in patients with suspected acute myocardial infarction who do not have hypoxemia at baseline is uncertain.In this registry-based randomized clinical trial, we used nationwide Swedish registries for patient enrollment and data collection. Patients with suspected myocardial infarction and an oxygen saturation of 90% or higher were randomly assigned to receive either supplemental oxygen (6 liters (...) during hospitalization was 946.5 ng per liter in the oxygen group and 983.0 ng per liter in the ambient-air group. The primary end point of death from any cause within 1 year after randomization occurred in 5.0% of patients (166 of 3311) assigned to oxygen and in 5.1% of patients (168 of 3318) assigned to ambient air (hazard ratio, 0.97; 95% confidence interval [CI], 0.79 to 1.21; P=0.80). Rehospitalization with myocardial infarction within 1 year occurred in 126 patients (3.8%) assigned to oxygen

2017 NEJM

136. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. (PubMed)

Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. The comparative efficacy of various anticoagulation strategies has not been clearly established in patients with acute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to current practice, which includes the use of radial-artery access for PCI and administration of potent P2Y12 inhibitors without the planned use of glycoprotein IIb/IIIa inhibitors.In this multicenter, randomized, registry (...) -based, open-label clinical trial, we enrolled patients with either ST-segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) who were undergoing PCI and receiving treatment with a potent P2Y12 inhibitor (ticagrelor, prasugrel, or cangrelor) without the planned use of glycoprotein IIb/IIIa inhibitors. The patients were randomly assigned to receive bivalirudin or heparin during PCI, which was performed predominantly with the use of radial-artery access. The primary end point

2017 NEJM

137. Incidence of myocardial infarction in pregnancy: a systematic review and meta-analysis of population-based studies. (PubMed)

Incidence of myocardial infarction in pregnancy: a systematic review and meta-analysis of population-based studies. Cardiac disease is one of the leading causes of indirect maternal death, and myocardial infarction (MI) is one of its most common aetiologies. The objectives of this systematic review and meta-analysis were to characterize the incidence of pregnancy-associated MI (PAMI), as well as the maternal mortality and the case-fatality rates due to PAMI.Articles were obtained by searching

Full Text available with Trip Pro

2017 European heart journal. Quality of care & clinical outcomes

138. Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration (PubMed)

Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration Women with acute myocardial infarction (MI) undergoing mechanical reperfusion remain at increased risk of adverse cardiac events and mortality compared with their male counterparts. Whether the benefits of new-generation drug-eluting stents (DES) are preserved in women with acute MI remains unclear.To

Full Text available with Trip Pro

2017 JAMA cardiology

139. Short- and Long-term Therapeutic Efficacies of Intravenous Transplantation of Bone Marrow Stem Cells on Cardiac Function in Rats with Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials. (PubMed)

Short- and Long-term Therapeutic Efficacies of Intravenous Transplantation of Bone Marrow Stem Cells on Cardiac Function in Rats with Acute Myocardial Infarction: A Meta-analysis of Randomized Controlled Trials.

2017 Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih

140. Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial

Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial In patients with a myocardial infarction (MI) 1 to 3 years earlier, treatment with ticagrelor + low-dose aspirin (ASA) reduces the risk of cardiovascular (CV) death, MI, or stroke compared with low-dose aspirin alone, but at an increased risk of major bleeding.The authors evaluated cost-effectiveness of ticagrelor + low-dose ASA in patients with prior MI within (...) the prior 3 years.The authors performed a prospective economic substudy alongside the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA. Medical resource use data were collected over a median 33-month follow-up. Costs

2017 EvidenceUpdates